CFDs are a leveraged product and can result in losses that exceed deposits. Please ensure you fully understand how CFDs work and what their risks are, and take care to manage your exposure. CFDs are a leveraged product and can result in losses that exceed deposits. Please ensure you fully understand how CFDs work and what their risks are, and take care to manage your exposure.

Earnings look ahead – Dignity, Prudential, Hikma Pharmaceuticals

A look at company earnings next week. 

Source: Bloomberg

Dignity (full-year earnings 14 March)

Dignity has begun to report tougher trading conditions, as consumers start to look for lower prices in the funeral sector.

Earnings are forecast to halve during the year, as the firm cuts prices to remain competitive. At 12-times earnings, the shares are much more interesting now than at the 20-times seen in previous years. A dividend of 3% looks interesting, and is well-covered by earnings. However, the net debt of over £500 million does provide some cause for concern. Dignity will have to work hard to regain business and pay down debt, a course that will result in a hit to earnings.

There has been little good news for Dignity, and while the share price has rallied of late, it remains a fraction of the levels seen in mid-2017. The first target is £12, being the top end of the recent gap lower, and then on to £15.79. The first area of support comes in at £7.36, and then on to £5.74p and 484p.

Prudential (full-year earnings 14 March)

It will be interesting to see if Prudential's numbers see a similar reaction to UK-focused peers Legal & General and Aviva.

These reported good numbers, but the reaction was broadly negative. It looks like Amazon is going to park its tanks on the insurer’s lawns. Prudential may get away with less of an impact from this for now, since its Asian exposure makes it well-positioned to benefit from economic growth in these countries, where Amazon’s influence is (for now) smaller. Earnings are expected to rise by 10% this year and 9% in the following, and at just 12-times earnings, the shares are not excessively priced.

A new record high for Prudential back in January has been followed up by a decline into support around £17.38. A bounce from there has run out of steam at £18.64, but a break above here would target the January high at £19.90. Below £17.38, £17.31 comes into play, and then £17.13.

Hikma Pharmaceuticals (full-year earnings 14 March)

Hikma's concerns are very similar to the rest of the sector, namely those covering the price headwinds of generic products.

Investors should expect an update on the generic version of its Advair drug, with the timing of the launch still uncertain. It may be that growth in the injectable division and branded franchises will help burnish performance somewhat. Finally, an improvement in branded sales should be seen, as both shipment delays and the devaluation of the Egyptian pound seen in the first half wear off.

Further falls for Hikma bring £6.02 and £5.36 into view. Meanwhile, a rally will target £10.82 and then £11.60. Rallies have been firmly sold for 18 months now, with little sign of a fundamental change in the story. 

This information has been prepared by IG, a trading name of IG Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.  Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. 

CFDs are a leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your initial deposit, so please ensure that you fully understand the risks involved.

Find articles by writer